Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $507,101.64 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 13,548 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the transaction, the insider directly owned 184,174 shares in the company, valued at $6,893,632.82. The trade was a 6.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jason Adair also recently made the following trade(s):

• On Monday, December 1st, Jason Adair sold 693 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total value of $22,307.67.
• On Tuesday, November 18th, Jason Adair sold 35,656 shares of Liquidia stock. The stock was sold at an average price of $30.03, for a total value of $1,070,749.68.
• On Monday, October 27th, Jason Adair sold 692 shares of Liquidia stock. The stock was sold at an average price of $22.93, for a total value of $15,867.56.

Liquidia Stock Performance

Shares of LQDA stock opened at $38.79 on Friday. The stock has a market capitalization of $3.37 billion, a PE ratio of -26.94, a PEG ratio of 0.68 and a beta of 0.48. The business’s 50 day simple moving average is $32.68 and its 200 day simple moving average is $25.77. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a one year low of $11.26 and a one year high of $41.57.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. As a group, research analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its stake in Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new position in shares of Liquidia in the 3rd quarter worth $38,887,000. Caprock Group LLC bought a new position in shares of Liquidia in the 3rd quarter worth $37,114,000. Tyro Capital Management LLC acquired a new stake in Liquidia in the 2nd quarter valued at $15,473,000. Finally, CenterBook Partners LP increased its stake in Liquidia by 811.7% during the 2nd quarter. CenterBook Partners LP now owns 1,103,850 shares of the company’s stock valued at $13,754,000 after purchasing an additional 982,778 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LQDA. Raymond James Financial reiterated a “strong-buy” rating and set a $47.00 price target on shares of Liquidia in a report on Tuesday, November 4th. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. BTIG Research reissued a “buy” rating and issued a $49.00 price target on shares of Liquidia in a research note on Friday, January 9th. HC Wainwright increased their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Needham & Company LLC lifted their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).